1832 Asset Management L.P. Bristol Myers Squibb CO Transaction History

1832 Asset Management L.P.

$55.8 Billion
Q3 2024

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$40.25 - $52.99 $2.96 Million - $3.9 Million	-73,659 Reduced 98.66%	1,000 $41,000
Q1 2024 May 14, 2024	SELL	$47.98 - $54.4 $2,494 - $2,828	-52 Reduced 0.07%	74,659 $4.05 Million
Q4 2023 Feb 13, 2024	BUY	$48.48 - $57.85 $775,922 - $925,889	16,005 Added 27.26%	74,711 $3.83 Million
Q3 2023 Nov 13, 2023	BUY	$57.89 - $64.73 $3.4 Million - $3.8 Million	58,706 New	58,706 $3.41 Million
Q2 2023 Aug 11, 2023	SELL	$63.71 - $70.74 $40,901 - $45,415	-642 Reduced 1.21%	52,258 $3.34 Million
Q1 2023 May 12, 2023	BUY	$65.71 - $74.53 $289,189 - $328,006	4,401 Added 9.07%	52,900 $3.67 Million
Q4 2022 Feb 14, 2023	SELL	$68.48 - $81.09 $698,153 - $826,712	-10,195 Reduced 17.37%	48,499 $3.49 Million
Q3 2022 Nov 14, 2022	BUY	$0.13 - $76.84 $1,497 - $885,119	11,519 Added 24.42%	58,694 $4.17 Million
Q2 2022 Aug 15, 2022	BUY	$72.62 - $79.98 $3.16 Million - $3.48 Million	43,455 Added 1168.15%	47,175 $3.63 Million
Q1 2022 May 16, 2022	BUY	$61.48 - $73.72 $209,032 - $250,648	3,400 Added 1062.5%	3,720 $269,000
Q4 2021 Feb 15, 2022	SELL	$53.63 - $62.52 $864,086 - $1.01 Million	-16,112 Reduced 98.05%	320 $20,000
Q3 2021 Nov 15, 2021	BUY	$59.17 - $69.31 $950,388 - $1.11 Million	16,062 Added 4341.08%	16,432 $1 Million
Q2 2021 Aug 16, 2021	SELL	$61.91 - $67.42 $15.4 Million - $16.8 Million	-248,794 Reduced 99.85%	370 $25,000
Q1 2021 May 17, 2021	SELL	$59.34 - $66.74 $20.2 Million - $22.7 Million	-340,424 Reduced 57.74%	249,164 $15.7 Million
Q4 2020 Feb 16, 2021	BUY	$57.74 - $65.43 $5.58 Million - $6.32 Million	96,620 Added 19.6%	589,588 $36.5 Million
Q3 2020 Nov 16, 2020	BUY	$57.43 - $63.64 $1.66 Million - $1.84 Million	28,855 Added 6.22%	492,968 $29.6 Million
Q2 2020 Aug 14, 2020	BUY	$54.82 - $64.09 $10.4 Million - $12.2 Million	189,760 Added 69.17%	464,113 $26.9 Million
Q1 2020 May 26, 2020	BUY	$46.4 - $67.43 $3.96 Million - $5.76 Million	85,437 Added 45.22%	274,353 $14.9 Million
Q1 2020 May 14, 2020	BUY	$46.4 - $67.43 $1.83 Million - $2.66 Million	39,498 Added 26.43%	188,916 $10.2 Million
Q4 2019 Feb 14, 2020	BUY	$49.21 - $64.19 $594,801 - $775,864	12,087 Added 8.8%	149,418 $9.47 Million
Q3 2019 Nov 14, 2019	BUY	$42.77 - $50.71 $3.15 Million - $3.74 Million	73,700 Added 115.82%	137,331 $6.79 Million
Q2 2019 Aug 14, 2019	BUY	$44.62 - $49.34 $1.45 Million - $1.6 Million	32,500 Added 104.4%	63,631 $2.79 Million
Q1 2019 May 15, 2019	BUY	$45.12 - $53.8 $1.38 Million - $1.64 Million	30,531 Added 5088.5%	31,131 $1.47 Million
Q3 2018 Nov 14, 2018	SELL	$55.19 - $62.25 $1.23 Million - $1.39 Million	-22,301 Reduced 97.38%	600 $37,000
Q2 2018 Aug 14, 2018	BUY	$50.53 - $62.98 $1.13 Million - $1.4 Million	22,301 Added 3716.83%	22,901 $1.17 Million
Q1 2018 May 15, 2018	SELL	$59.92 - $68.98 $1.53 Million - $1.76 Million	-25,481 Reduced 97.7%	600 $38,000
Q4 2017 Feb 14, 2018	BUY	$59.94 - $65.35 $954,604 - $1.04 Million	15,926 Added 156.83%	26,081 $1.54 Million
Q3 2017 Nov 14, 2017	BUY	$55.23 - $63.74 $560,860 - $647,279	10,155	10,155 $629,000

Others Institutions Holding BMY

# of Institutions

2,533

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

Vanguard Group Inc Valley Forge, PA

189M
Shares

$11.1 Billion
0.18% of portfolio
Black Rock Inc. New York, NY

159M
Shares

$9.34 Billion
0.15% of portfolio
State Street Corp Boston, MA

92.9M
Shares

$5.47 Billion
0.2% of portfolio
Jpmorgan Chase & CO New York, NY

77.9M
Shares

$4.59 Billion
0.33% of portfolio
Charles Schwab Investment Management Inc San Francisco, CA

61M
Shares

$3.59 Billion
0.61% of portfolio

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $125B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of 1832 Asset Management L.P., based on Form 13F filings with the SEC.

News

Stay updated on 1832 Asset Management L.P. with notifications on news.

Account